0%
Print report
Variant interpretation report

WFS1 c.1675G>A, p.Ala559Thr

NM_006005.3:c.1675G>A NP_005996.2:p.(Ala559Thr) Missense · exon 8 View identifiers
Classification
Uncertain significance

Variant description:

The WFS1 NM_006005.3:c.1675G>A (NP_005996.2:p.(Ala559Thr)) missense variant has previously been reported in somatic cancers (COSMIC; COSV113903602, n = 1 time). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About WFS1

WFS1 encodes wolframin, a transmembrane protein found mainly in the endoplasmic reticulum and involved in the function of cells such as pancreatic beta cells and neurons. Changes in WFS1 can cause Wolfram syndrome, an inherited disorder characterized by diabetes mellitus, optic atrophy, hearing loss, and other neurological problems, as well as autosomal dominant nonsyndromic deafness. WFS1 has no established role in cancer.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 0
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: no adjudicated pathogenic or benign criteria are applied under the generic ACMG/AMP 2015 fallback combination rules.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
7,829 / 1,612,772 alleles

gnomAD v4.1: 7,829 / 1,612,772 alleles. Recorded AF 0.00485437. Recorded homozygote count 20.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00392318; MAF= 0.39232%, 1106/281914 alleles, homozygotes = 1) and has highest observed frequency in the European (Finnish) population (AF= 0.00578485; MAF= 0.57849%, 141/24374 alleles, homozygotes = 0); grpmax FAF= 0.00546862.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0033119774133999347, 61/18418 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.407 recorded score

Recorded REVEL score: 0.407. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
16 reported laboratory submissions

10 Likely benign · 6 Benign. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV113903602, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 0 met · 7 not met · 17 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No patient-specific parental testing, de novo observation, affected-relative segregation, or affected-relative non-segregation evidence was supplied; all four criteria remain not assessed.

No VCEP covers WFS1 in this case; generic ACMG/AMP 2015 definitions govern.

PS4 could not be numerically assessed because verified case-control counts or an OR/RR with a confidence interval were unavailable.

PP5 and BP6 were not met because the exact ClinVar record has no expert-panel classification; its benign/likely benign laboratory assertions are insufficient for these restricted rules.

Not met · 7 · evaluated, threshold not reached

PM2 ACMG_2015Not met: gnomAD v4.1 AF is 0.00485437, substantially above the <=0.0001 PM2 supporting threshold, with 20 homozygotes observed. Details ▾Hide ▴
Reasoning

PM2 is not met. The supplied generic PM2 supporting threshold is <=0.0001. In default all-comers gnomAD v4.1, the variant has AF=0.00485437 from 7,829/1,612,772 alleles and 20 homozygotes; gnomAD v2.1 has AF=0.00392318 from 1,106/281,914 alleles and 1 homozygote. The variant is therefore present at frequencies substantially above the PM2 threshold rather than absent or extremely rare in controls. The non-cancer subsets are also clearly above the threshold: 0.00398624 in gnomAD v2.1 non-cancer exomes and 0.00331775 in gnomAD v3.1 non-cancer genomes.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers: AF=0.00485437 (7,829/1,612,772) with 20 homozygotes.
  • gnomAD v2.1 all-comers: AF=0.00392318 (1,106/281,914) with 1 homozygote.
  • Non-cancer subsets are also above the threshold: gnomAD v2.1 non-cancer exomes AF=0.00398624 (941/236,062), and gnomAD v3.1 non-cancer genomes AF=0.00331775 (491/147,992).
  • The supplied generic PM2 supporting calibration is <=0.0001 under the ClinGen SVI recommendation (identified in the prompt with PMID:25741868).
Sources
PP3 ACMG_2015Not met: REVEL 0.407 is below the PP3 supporting threshold of 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_006005.3:c.1675G>A (p.Ala559Thr), so the governing generic rule requires the missense REVEL path only; SpliceAI is not evidence for PP3 in this situation. REVEL is 0.407, which is below the generic PP3 supporting threshold of >=0.644. BayesDel is not used because no generic ACMG-strength calibration is established. Therefore PP3 is not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense SNV, NM_006005.3:c.1675G>A, NP_005996.2:p.(Ala559Thr); this selects the REVEL-only path and excludes SpliceAI from PP3/BP4 for this variant.
  • Local REVEL predictor lookup: score 0.407 for NM_006005.3:c.1675G>A.
  • Generic ClinGen SVI REVEL calibration: PP3 supporting requires REVEL >=0.644; Pejaver et al. 2022, American Journal of Human Genetics, PMID:36413997.
  • BayesDel score -0.139222 was not used because the governing generic rules provide no ACMG-strength calibration for BayesDel.
Sources
revel
PP5 ACMG_2015Not met: ClinVar has zero expert-panel submissions and reports benign/likely benign assertions, not an expert-panel pathogenic or likely-pathogenic classification. Details ▾Hide ▴
Reasoning

The generic ACMG/AMP rule concerns a reputable source reporting the variant as pathogenic when the underlying evidence is unavailable for independent evaluation. The exact ClinVar record for NM_006005.3:c.1675G>A (p.Ala559Thr) contains no expert-panel submission and reports benign/likely benign laboratory assertions, not an expert-panel pathogenic or likely-pathogenic classification. Therefore PP5 is not met.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 95322, exact variant NM_006005.3(WFS1):c.1675G>A (p.Ala559Thr): expert_panels is empty; submissions summarize 10 Likely benign and 6 Benign clinical-laboratory assertions, with no expert-panel classification.
Sources
BA1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 0.0055781, below the 0.05 BA1 threshold, in a population with 1,180,036 observed alleles. Details ▾Hide ▴
Reasoning

BA1 is not met. Under the generic stand-alone threshold supplied for this case, the filtering population frequency must be at least 0.05. The default all-comers gnomAD data show grpmax FAF=0.0055781 in gnomAD v4.1, with the highest-frequency population (European non-Finnish) having 6,717 observed alternate alleles out of 1,180,036; this is below 0.05 and the qualifying population exceeds the 2,000-observed-allele reliability requirement. gnomAD v2.1 likewise has grpmax FAF=0.00546862, below 0.05. The small HGDP:Cambodian point estimate of 0.05 in the non-cancer v3.1 subset is 1/20 alleles and is excluded because its population sample is below 2,000 observed alleles and its filtering FAF is not at least 0.05.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers: AF=0.00485437 (7,829/1,612,772), grpmax FAF=0.0055781; European non-Finnish population AF=0.0056922 (6,717/1,180,036).
  • gnomAD v2.1 all-comers: AF=0.00392318 (1,106/281,914), grpmax FAF=0.00546862.
  • The supplied generic BA1 calibration is >=0.05 from ACMG/AMP 2015 (PMID:25741868); filtering FAF rather than a small-population point estimate was used as instructed.
Sources
BS1 ACMG_2015Not met: default gnomAD v4.1 grpmax FAF is 0.0055781, below the generic BS1 threshold of 0.01 despite adequate population size. Details ▾Hide ▴
Reasoning

BS1 is not met on the supplied generic default. The required filtering allele-frequency figure is the grpmax FAF, not the popmax point estimate. In default all-comers gnomAD v4.1, grpmax FAF=0.0055781, and in gnomAD v2.1 it is 0.00546862; both are below the generic BS1 threshold of 0.01. The highest-frequency qualifying v4 population is European non-Finnish with 1,180,036 observed alleles, so the result is not driven by a small population. The non-cancer subsets are concordant: gnomAD v2.1 non-cancer exomes grpmax FAF=0.00559864 and gnomAD v3.1 non-cancer genomes grpmax FAF=0.00515019. No maximum-credible-frequency calculation is needed because the filtering FAF does not reach the default threshold.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v4.1 all-comers: grpmax FAF=0.0055781; highest-frequency European non-Finnish population has 6,717/1,180,036 observed alleles.
  • gnomAD v2.1 all-comers: grpmax FAF=0.00546862.
  • The available non-cancer subsets are concordant: gnomAD v2.1 non-cancer exomes grpmax FAF=0.00559864 and gnomAD v3.1 non-cancer genomes grpmax FAF=0.00515019.
  • The supplied generic BS1 calibration is >=0.01, described as the generic SVI default with per-gene derivation preferred under Whiffin et al. 2017 (PMID:28518168).
Sources
BP4 ACMG_2015Not met: REVEL 0.407 exceeds the BP4 supporting threshold of <=0.29. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_006005.3:c.1675G>A (p.Ala559Thr), so the governing generic rule requires the missense REVEL path only; SpliceAI is not evidence for BP4 in this situation. REVEL is 0.407, which exceeds the generic BP4 supporting threshold of <=0.29 and is not within a benign REVEL range. BayesDel is not used because no generic ACMG-strength calibration is established. Therefore BP4 is not met.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
  • Variant consequence: missense SNV, NM_006005.3:c.1675G>A, NP_005996.2:p.(Ala559Thr); this selects the REVEL-only path and excludes SpliceAI from PP3/BP4 for this variant.
  • Local REVEL predictor lookup: score 0.407 for NM_006005.3:c.1675G>A.
  • Generic ClinGen SVI REVEL calibration: BP4 supporting requires REVEL <=0.29; Pejaver et al. 2022, American Journal of Human Genetics, PMID:36413997.
  • BayesDel score -0.139222 was not used because the governing generic rules provide no ACMG-strength calibration for BayesDel.
Sources
revel
BP6 ACMG_2015Not met: ClinVar's benign/likely benign record has zero expert-panel submissions, so non-expert laboratory assertions cannot trigger BP6. Details ▾Hide ▴
Reasoning

The generic ACMG/AMP rule concerns a reputable source reporting the variant as benign when the underlying evidence is unavailable for independent evaluation. Although ClinVar contains benign and likely benign laboratory submissions, the exact record has zero expert-panel submissions; ordinary laboratory submissions, aggregate labels, and non-expert assertions do not satisfy the required expert-panel condition. Therefore BP6 is not met.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 95322, exact variant NM_006005.3(WFS1):c.1675G>A (p.Ala559Thr): expert_panels is empty; the record contains only laboratory submissions summarized as Benign/Likely benign.
Sources

Not assessed · 17 · no assessment recorded

PS1 ACMG_2015Not assessed: A559T was reported but not established as pathogenic, and the exact ClinVar record contains benign or likely benign submissions. Details ▾Hide ▴
Reasoning

The variant is NM_006005.3:c.1675G>A, p.(Ala559Thr). PMID:12565131 reports that A559T was genotyped but was absent from the bipolar-disorder cases and controls; it does not establish A559T as pathogenic. ClinVar variation 95322 is the exact A559T variant and contains benign/likely benign submissions, not a previously established pathogenic variant. The available evidence therefore does not establish a different nucleotide change producing the same amino-acid substitution with a pathogenic classification, and the criterion cannot be adjudicated as met.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinVar variation 95322 identifies the exact variant as NM_006005.3(WFS1):c.1675G>A (p.Ala559Thr) and reports benign/likely benign submissions with no expert-panel submission.
  • Kato et al. 2003, PMID:12565131, abstract: "None had the A559T and A602V mutations, and no association of G576S and H611R with bipolar disorder was found." The paper does not establish A559T as pathogenic.
Still missing
  • A curated pathogenic report for a different nucleotide change producing p.Ala559Thr is not available.
  • The available exact-variant literature does not establish pathogenicity.
Sources
PS2 ACMG_2015Not assessed: no documented patient-specific de novo observation confirms both maternity and paternity for NM_006005.3:c.1675G>A. Details ▾Hide ▴
Reasoning

PS2 cannot be assessed because the supplied evidence contains no patient-specific observation documenting a de novo NM_006005.3:c.1675G>A variant with both maternity and paternity confirmed, disease-consistent phenotype, and no family history.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The supplied case records contain no patient-specific proband-parent trio result or confirmed maternity and paternity for NM_006005.3:c.1675G>A.
Still missing
  • Patient-specific clinical report identifying the disease phenotype and family history.
  • Variant testing results for the proband and both biological parents, with maternity and paternity confirmation.
Sources
PS3 ACMG_2015Not assessed: no variant-specific well-established functional study provides a damaging-effect result for WFS1 p.Ala559Thr. Details ▾Hide ▴
Reasoning

No variant-specific, well-established in vitro or in vivo functional study was identified for WFS1 NM_006005.3:c.1675G>A (p.Ala559Thr). The extracted full-text papers PMID:26467025 and PMID:33057194 do not mention WFS1 or this variant and provide no assay result, so there is no validated functional evidence from which to assign PS3 or calibrate its strength.

Rule
PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • PMID:26467025 was reviewed from its extracted full text; it does not mention WFS1 or p.(A559T) and describes no WFS1-specific assay.
  • PMID:33057194 was reviewed from its extracted full text; it does not mention WFS1 or p.(A559T) and provides no variant-specific functional result.
Still missing
  • A variant-specific functional assay with appropriate controls and biological relevance is required to assess PS3.
Sources
PS4 ACMG_2015Not assessed: no verified affected-versus-control counts, odds ratio, or confidence interval were available for c.1675G>A, so the PS4 >5.0 and CI-excluding-1.0 requirements cannot be evaluated. Details ▾Hide ▴
Reasoning

No VCEP applies. The generic ACMG/AMP rule requires a case-control prevalence comparison and, for the specified threshold path, an OR or RR >5.0 with a confidence interval excluding 1.0. The literature packet indexed PS4 candidate papers (PMID:11244483, PMID:11694551, PMID:11920861, PMID:15277431, PMID:15852062, PMID:20301607, PMID:20301750, PMID:25133958, and PMID:32179840), but the supplied verified extracts do not provide exact-variant affected-control counts, an OR/RR, or a 95% CI for NM_006005.3:c.1675G>A (p.Ala559Thr). Therefore no valid numeric inequality can be written: OR/RR is unavailable, so OR/RR > 5.0 and CI excluding 1.0 cannot be assessed. The available gnomAD frequency is a population observation, not a disease case-control comparison by itself.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • literature_pass.json criteria_index lists PMID:11244483, PMID:11694551, PMID:11920861, PMID:15277431, PMID:15852062, PMID:20301607, PMID:20301750, PMID:25133958, and PMID:32179840 as PS4 leads; ai_classified_papers is empty.
  • The supplied paper extracts for PMID:26467025 and PMID:33057194 state that neither paper contains WFS1 c.1675G>A/p.(A559T) variant-specific clinical or population evidence.
  • gnomAD v4.1 reports population AF 0.00485437 overall and 0.00569220 in European non-Finnish individuals, but no affected-case frequency is supplied for this variant.
Still missing
  • Exact-variant affected-case and unaffected/control counts or a directly reported OR/RR with its 95% CI.
  • Full-text verification for the PS4-indexed papers lacking a supplied paper_extracts entry.
Sources
PM1 ACMG_2015Not assessed: Cancer Hotspots returned no WFS1 A559 result, while no authoritative WFS1 critical-domain list is available for residue 559. Details ▾Hide ▴
Reasoning

The variant is p.Ala559Thr. The Cancer Hotspots search for WFS1 A559 returned no result, so the supplied evidence does not establish a hotspot. No VCEP covers WFS1 and vcep_materials.json contains no authoritative WFS1 domain table; consequently, no complete approved critical-domain list is available to determine whether residue 559 lies in a well-established functional domain without benign variation. PM1 cannot be adjudicated from the available evidence.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Cancer Hotspots query "WFS1 A559" returned no result and the recorded evidence sentence states: "This variant does not lie in a statistically significant hotspot."
  • The case has no WFS1 VCEP and vcep_materials.json has an empty domain_tables object, so no authoritative VCEP domain entry can be checked for residue 559.
Still missing
  • A gene-specific, well-established functional-domain annotation for WFS1 residue 559 is unavailable.
  • Evidence that the relevant domain lacks benign variation is unavailable.
Sources
PM3 ACMG_2015Not assessed: no affected-proband observation documents c.1675G>A in trans with a pathogenic WFS1 variant or establishes phase by parental or offspring testing. Details ▾Hide ▴
Reasoning

The generic PM3 rule applies to recessive disorders when the variant is detected in trans with a pathogenic variant, with parental or offspring testing required to determine phase. WFS1-related Wolfram syndrome is described in the case evidence as autosomal recessive, but the available evidence does not document an affected proband carrying NM_006005.3:c.1675G>A with a second pathogenic WFS1 variant, nor does it provide parent/offspring testing or phase. The ClinVar record reports classifications and cited publications but does not supply usable trans-phase evidence for this variant. Therefore PM3 cannot be assessed.

Rule
For recessive disorders, detected in trans with a pathogenic variant ... This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • ClinVar variation 95322 reports NM_006005.3(WFS1):c.1675G>A (p.Ala559Thr) as Benign/Likely benign with multiple submitters, but the supplied record contains no documented affected-proband compound-heterozygous observation, pathogenic allele in trans, or parent/offspring phase result.
  • The case evidence describes Wolfram syndrome as an autosomal-recessive disorder, but provides no variant-specific trans-phase observation for c.1675G>A.
Still missing
  • Affected-proband data with a second pathogenic WFS1 variant are not documented.
  • Parental or offspring testing establishing trans phase is not documented.
Sources
PM5 ACMG_2015Not assessed: no pathogenic alternate missense at Ala559 is established, and the PM5 candidate collection contains zero same-residue candidates. Details ▾Hide ▴
Reasoning

The observed change is p.Ala559Thr. The supplied PM5 candidate collection contains zero same-residue candidates and no pathogenic comparator. The available PMID:12565131 abstract discusses A559T and other WFS1 substitutions but does not establish a different missense change at Ala559 as pathogenic. A pathogenic alternate missense at residue 559 is therefore not established by the available evidence.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • pm5_candidates.json records same_residue_candidates=0, expert_panel_plp_candidates=0, and an empty candidates list; it does not provide a pathogenic comparator.
  • Kato et al. 2003, PMID:12565131, reports A559T, A602V, G576S, and H611R in a bipolar-disorder association study but does not establish a pathogenic alternate missense change at Ala559.
Still missing
  • A curated pathogenic alternate missense variant at WFS1 residue 559 is not available.
Sources
pm5_candidatesPMID:12565131 ↗
PM6 ACMG_2015Not assessed: no patient-specific observation documents NM_006005.3:c.1675G>A as assumed de novo without parental confirmation. Details ▾Hide ▴
Reasoning

PM6 cannot be assessed because the supplied evidence contains no patient-specific observation that the variant is assumed de novo without confirmation of paternity and maternity.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The supplied case records contain no patient-specific de novo report or proband-parent testing result for NM_006005.3:c.1675G>A.
Still missing
  • Patient-specific report describing the variant as de novo or providing proband-parent testing results.
  • Documentation of whether maternity and paternity were or were not confirmed.
Sources
PP1 ACMG_2015Not assessed: 0 affected family-member transmissions or informative meioses are documented for NM_006005.3:c.1675G>A. Details ▾Hide ▴
Reasoning

PP1 cannot be assessed because the supplied evidence provides no affected family members, informative meioses, phenotype-linked variant transmissions, or quantitative segregation observations for NM_006005.3:c.1675G>A.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
  • The supplied case records contain no pedigree, affected-relative genotype, phenotype-linked transmission, or informative meiosis for NM_006005.3:c.1675G>A.
Still missing
  • Pedigree identifying affected relatives and their clinical phenotypes.
  • Genotypes and segregation results for affected and unaffected informative relatives.
PP2 ACMG_2015Not assessed: the required WFS1 gene-level evidence for low benign missense variation and a common missense disease mechanism is unavailable. Details ▾Hide ▴
Reasoning

The variant is a missense substitution in WFS1. The supplied evidence does not provide a gene-level analysis demonstrating both a low rate of benign missense variation and that missense variants are a common mechanism of disease. The presence of p.Ala559Thr in population databases and benign/likely benign ClinVar submissions is not a substitute for the required gene-level missense-spectrum assessment, so PP2 is not assessed.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • The case identifies p.Ala559Thr as a missense variant but supplies no gene-level missense constraint, benign-missense-rate, or mechanism analysis that satisfies both PP2 components.
Still missing
  • A validated WFS1 missense constraint or benign-missense-rate analysis is unavailable.
  • A validated assessment showing missense variants are a common WFS1 disease mechanism is unavailable.
PP4 ACMG_2015Not assessed: the supplied evidence lacks a patient phenotype or family-history description demonstrating high specificity for a single-genetic-etiology disease. Details ▾Hide ▴
Reasoning

The generic ACMG/AMP rule requires a patient phenotype or family history highly specific for a disease with a single genetic etiology. The supplied case evidence identifies the variant and WFS1-related disease labels but does not provide the patient's phenotype, family history, or a specificity assessment sufficient to apply PP4.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • The case summary identifies WFS1 and ClinVar condition labels, but no patient-level phenotype or family-history description is supplied.
Still missing
  • Patient phenotype and family-history details with an assessment of specificity for the relevant WFS1-associated disease.
BS2 ACMG_2015Not assessed: gnomAD v4.1 reports 20 homozygotes, but no record establishes that any was a healthy adult with expected early full penetrance. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available population record. gnomAD v4.1 reports 20 homozygotes overall, including 15 in the European non-Finnish population, and gnomAD v2.1 reports 1 homozygote; however, the records do not identify any carrier as a healthy adult, provide age or phenotype follow-up, or establish that full penetrance at an early age is expected for the relevant WFS1 disorder. A homozygote count alone therefore does not satisfy the BS2 definition.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 all-comers reports 20 homozygotes overall and 15 in the European non-Finnish population; gnomAD v2.1 reports 1 homozygote.
  • The population records provide aggregate homozygote counts but no individual health status, adult age confirmation, phenotype assessment, or penetrance assessment.
Still missing
  • No individual-level evidence confirms that the reported homozygotes were healthy adults.
  • The relevant disorder's early-age full-penetrance assumption is not established for this WFS1 missense variant or phenotype.
Sources
BS3 ACMG_2015Not assessed: no variant-specific well-established functional study shows that WFS1 p.Ala559Thr has no damaging effect. Details ▾Hide ▴
Reasoning

No variant-specific, well-established in vitro or in vivo functional study was identified for WFS1 NM_006005.3:c.1675G>A (p.Ala559Thr) showing preserved protein function or splicing. The extracted full-text papers PMID:26467025 and PMID:33057194 do not mention WFS1 or this variant and provide no assay result, so BS3 cannot be assessed.

Rule
BS3: Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:26467025 was reviewed from its extracted full text; it does not mention WFS1 or p.(A559T) and describes no WFS1-specific assay.
  • PMID:33057194 was reviewed from its extracted full text; it does not mention WFS1 or p.(A559T) and provides no variant-specific functional result.
Still missing
  • A variant-specific functional assay demonstrating no damaging effect on protein function or splicing is required to assess BS3.
Sources
BS4 ACMG_2015Not assessed: 0 tested affected relatives are documented as lacking NM_006005.3:c.1675G>A, so non-segregation cannot be established. Details ▾Hide ▴
Reasoning

BS4 cannot be assessed because the supplied evidence documents no affected family members who were tested and found not to carry NM_006005.3:c.1675G>A; absence of segregation data is not evidence of lack of segregation.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The supplied case records contain no tested affected relative who lacks NM_006005.3:c.1675G>A and no family-level non-segregation analysis.
Still missing
  • Pedigree and phenotype data for affected relatives.
  • Variant test results for affected relatives, including any confirmed non-carriers.
BP1 ACMG_2015Not assessed: the available evidence does not establish that WFS1 disease is caused primarily by truncating variants. Details ▾Hide ▴
Reasoning

The variant is a missense substitution in WFS1. The supplied case evidence does not establish that WFS1 disease is caused primarily by truncating variants, nor does it provide a validated comparison of truncating versus missense disease mechanisms. Therefore, the gene-level prerequisite for BP1 cannot be adjudicated.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • The case identifies p.Ala559Thr as a missense variant but supplies no gene-level variant-spectrum analysis establishing that WFS1 disease is primarily caused by truncating variants.
Still missing
  • A validated WFS1 disease-variant spectrum comparing truncating and missense mechanisms is unavailable.
  • Evidence that truncating variants are the primary known disease mechanism is unavailable.
BP2 ACMG_2015Not assessed: no individual-level observation establishes c.1675G>A in cis or trans with a pathogenic WFS1 variant, and no phase result is documented. Details ▾Hide ▴
Reasoning

The generic BP2 rule requires either observation in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observation in cis with a pathogenic variant in any inheritance pattern. No affected-proband or other individual-level observation in the supplied evidence establishes c.1675G>A in trans or cis with a pathogenic WFS1 variant, and no phase testing result is documented. The ClinVar record reports classifications and cited publications but does not provide usable cis/trans co-occurrence evidence for this variant. Therefore BP2 cannot be assessed.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • ClinVar variation 95322 reports NM_006005.3(WFS1):c.1675G>A (p.Ala559Thr) as Benign/Likely benign with multiple submitters, but the supplied record contains no documented cis/trans co-occurrence with a pathogenic WFS1 variant or phase result.
  • The available case evidence contains no affected-proband observation establishing the allelic relationship required by BP2.
Still missing
  • No documented cis/trans co-occurrence observation with a pathogenic WFS1 variant.
  • No phase-testing result is documented.
Sources
BP5 ACMG_2015Not assessed: no case-level alternate molecular diagnosis or pathogenic alternative explanation was supplied for a carrier of c.1675G>A. Details ▾Hide ▴
Reasoning

The generic ACMG/AMP rule requires the variant to be found in a case with an alternate molecular basis for disease. The supplied evidence contains no case-level alternate molecular diagnosis, pathogenic second variant, or other molecular explanation tied to a patient carrying NM_006005.3:c.1675G>A; the ClinVar condition list is not such evidence.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • The supplied case and ClinVar evidence contain no documented alternate molecular basis for disease in a case carrying this exact variant.
Still missing
  • A documented case carrying this variant together with an independently established alternate molecular basis for the relevant disease.
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_006005.3:c.1675G>A in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Ala559Thr). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_006005.3:c.1675G>A in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Ala559Thr). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_006005.3:c.1675G>A in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Ala559Thr). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_006005.3:c.1675G>A in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Ala559Thr). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
WFS1
Transcript
NM_006005.3
Coding (HGVS c.)
NM_006005.3:c.1675G>A
Protein (HGVS p.)
NP_005996.2:p.(Ala559Thr)
GRCh38
chr4:6301470 G>A
GRCh37
chr4:6303197 G>A
Location and type
Exon 8 · missense
ClinVar
95322
COSMIC
COSV113903602

Gene diagram

Every interpreted variant in WFS1, mapped onto the exon structure of NM_006005.3. Select a row to find it on the plot.

WFS1NM_006005.3
Fetching transcript structure from UCSC…
gnomAD v4.1 7,829 / 1,612,772 alleles AF 0.00485 · 20 homozygotes · FAF 0.00558
gnomAD v2.1 1,106 / 281,914 alleles AF 0.00392 · 1 homozygotes · FAF 0.00547
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0.0049 · 7829 / 1,612,772 alleles · 20 hom · FAF 0.0056
European (non-Finnish)6717 / 1,180,036 0.005715 hom
European (Finnish)353 / 62,600 0.00561 hom
Remaining individuals250 / 62,498 0.004
South Asian330 / 91,076 0.00364 hom
Middle Eastern21 / 6,062 0.0035
Admixed American88 / 60,030 0.0015
African/African American65 / 75,068 0.00087
Ashkenazi Jewish4 / 29,608 0.00014
East Asian1 / 44,882 2.2e-05
0 alternate alleles recorded in 1 other group: Amish.

gnomAD v2.1

AF 0.0039 · 1106 / 281,914 alleles · 1 hom · FAF 0.0055
European (Finnish)141 / 24,374 0.0058
European (non-Finnish)743 / 129,018 0.0058
Remaining individuals29 / 7,216 0.004
South Asian118 / 30,614 0.00391 hom
Admixed American51 / 35,438 0.0014
African/African American23 / 24,938 0.00092
Ashkenazi Jewish1 / 10,364 9.6e-05
0 alternate alleles recorded in 1 other group: East Asian.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00485437; MAF= 0.48544%, 7829/1612772 alleles, homozygotes = 20) and has highest observed frequency in the European (non-Finnish) population (AF= 0.0056922; MAF= 0.56922%, 6717/1180036 alleles, homozygotes = 15); grpmax FAF= 0.0055781.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00392318; MAF= 0.39232%, 1106/281914 alleles, homozygotes = 1) and has highest observed frequency in the European (Finnish) population (AF= 0.00578485; MAF= 0.57849%, 141/24374 alleles, homozygotes = 0); grpmax FAF= 0.00546862.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0033119774133999347, 61/18418 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -114 bp
0.000
SpliceAI acceptor gainat +78 bp
0.000
SpliceAI donor lossat -54 bp
0.000
SpliceAI donor gainat +236 bp
0.000
Pangolin splice lossmagnitude shown
-0.001
Pangolin splice gain
0.001

Other predictors

REVEL
0.407
BayesDel
-0.139

How the predictions were used

PP3 ACMG_2015Not met: REVEL 0.407 is below the PP3 supporting threshold of 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_006005.3:c.1675G>A (p.Ala559Thr), so the governing generic rule requires the missense REVEL path only; SpliceAI is not evidence for PP3 in this situation. REVEL is 0.407, which is below the generic PP3 supporting threshold of >=0.644. BayesDel is not used because no generic ACMG-strength calibration is established. Therefore PP3 is not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense SNV, NM_006005.3:c.1675G>A, NP_005996.2:p.(Ala559Thr); this selects the REVEL-only path and excludes SpliceAI from PP3/BP4 for this variant.
  • Local REVEL predictor lookup: score 0.407 for NM_006005.3:c.1675G>A.
  • Generic ClinGen SVI REVEL calibration: PP3 supporting requires REVEL >=0.644; Pejaver et al. 2022, American Journal of Human Genetics, PMID:36413997.
  • BayesDel score -0.139222 was not used because the governing generic rules provide no ACMG-strength calibration for BayesDel.
Sources
revel
BP4 ACMG_2015Not met: REVEL 0.407 exceeds the BP4 supporting threshold of <=0.29. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, NM_006005.3:c.1675G>A (p.Ala559Thr), so the governing generic rule requires the missense REVEL path only; SpliceAI is not evidence for BP4 in this situation. REVEL is 0.407, which exceeds the generic BP4 supporting threshold of <=0.29 and is not within a benign REVEL range. BayesDel is not used because no generic ACMG-strength calibration is established. Therefore BP4 is not met.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
  • Variant consequence: missense SNV, NM_006005.3:c.1675G>A, NP_005996.2:p.(Ala559Thr); this selects the REVEL-only path and excludes SpliceAI from PP3/BP4 for this variant.
  • Local REVEL predictor lookup: score 0.407 for NM_006005.3:c.1675G>A.
  • Generic ClinGen SVI REVEL calibration: BP4 supporting requires REVEL <=0.29; Pejaver et al. 2022, American Journal of Human Genetics, PMID:36413997.
  • BayesDel score -0.139222 was not used because the governing generic rules provide no ACMG-strength calibration for BayesDel.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_006005.3:c.1675G>A in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Ala559Thr). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.407. BayesDel score = -0.139222.

8 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Recorded publications

  • No association of mutations and mRNA expression of WFS1/wolframin with bipolar disorder in humans.
    Kato T et al. · 2003
    The study genotyped four WFS1 missense variants in 184 patients with bipolar disorder and 207 controls. A559T and A602V were absent from both groups, while G576S and H611R showed no association with bipolar disorder; the paper does not establish a pathogenic classification for A559T or a pathogenic alternate at Ala559.
    Names this variant
    PMID 12565131 ↗
    Quoted passage
    None had the A559T and A602V mutations, and no association of G576S and H611R with bipolar disorder was found.

    Abstract

  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    This paper does not explicitly mention WFS1, c.1675G>A, or NP_005996.2:p.(A559T), and provides no variant-specific functional assay or gene-specific result relevant to this variant.
    Does not name this variant
    PMID 26467025 ↗
  • Evidence for 28 genetic disorders discovered by combining healthcare and research data.
    Kaplanis J et al. · 2020
    This paper does not mention WFS1, c.1675G>A, or p.(A559T), and provides no variant-specific, gene-specific, functional, clinical, segregation, or population-frequency information relevant to this variant.
    Does not name this variant
    PMID 33057194 ↗
  • Mutation screening of the Wolfram syndrome gene in psychiatric patients.
    Torres R et al. · 2001
    No paper-specific finding is recorded.
    PMID 11244483 ↗
  • Wolfram syndrome: a clinical and molecular genetic analysis.
    Eller P et al. · 2001
    No paper-specific finding is recorded.
    PMID 11694551 ↗
  • Is there a relationship between Wolfram syndrome carrier status and suicide?
    No paper-specific finding is recorded.
    PMID 11920861 ↗
  • Phenotype-genotype correlations in a series of wolfram syndrome families.
    Smith CJ et al. · 2004
    No paper-specific finding is recorded.
    PMID 15277431 ↗
  • Wolframin mutations and hospitalization for psychiatric illness.
    No paper-specific finding is recorded.
    PMID 15852062 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00485437; MAF= 0.48544%, 7829/1612772 alleles, homozygotes = 20) and has highest observed frequency in the European (non-Finnish) population (AF= 0.0056922; MAF= 0.56922%, 6717/1180036 alleles, homozygotes = 15); grpmax FAF= 0.0055781.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00392318; MAF= 0.39232%, 1106/281914 alleles, homozygotes = 1) and has highest observed frequency in the European (Finnish) population (AF= 0.00578485; MAF= 0.57849%, 141/24374 alleles, homozygotes = 0); grpmax FAF= 0.00546862.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0033119774133999347, 61/18418 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Likely benign (10 clinical laboratories) and as Benign (6 clinical laboratories). (ClinVarID = 95322)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.407. BayesDel score = -0.139222.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV113903602, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.